Dientamoebiasis

Summary

Dientamoebiasis (MONDO:0024608) is a disease and 2 clinical trials. Top therapeutic interventions include metronidazole. A subtype of protozoa infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	dientamoebiasis
Mondo ID	MONDO:0024608
MeSH	D004030
DOID	DOID:946
SNOMED CT	67915005
UMLS	C0012147
MedGen	41551
Is cancer (heuristic)	no

Also known as: Dientamoeba caused disease or disorder · Dientamoeba disease or disorder · Dientamoeba infectious disease · Dientamoebiases

Disease family

This is a subtype of protozoa infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › dientamoebiasis

Related subtypes (14): primary amebic meningoencephalitis, granulomatous amebic encephalitis, trypanosomiasis, giardiasis, protozoal dysentery, trichomoniasis, malaria, Acanthamoeba keratitis, amebiasis, babesiosis, balantidiasis, coccidiosis, theileriasis, leishmaniasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01314976	PHASE4	COMPLETED	Treatment Study of Metronidazole to Treat Dientamoebiasis in Children
NCT02105714	Not specified	COMPLETED	Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
METRONIDAZOLE	4	1